Pranati Shah

Dr. Pranati Shah

Auto-generated profile, based on publicly available information

Dr. Pranati Shah


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2025 in ESMO Gastrointestinal Oncology
Verified
Journal Article
Open access
DCDani Ran Castillo
Dani Ran Castillo
MGMengni Guo
Mengni Guo
PSP. Shah
P. Shah
MHM. Hazeltin
M. Hazeltin
DTD. Tai
D. Tai
DLDaneng Li
Daneng Li

18 December 2025 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
PSPranati Shah
Pranati Shah
CLCarol D. Lee
Carol D. Lee
WJWon Jin Jeon
Won Jin Jeon
ADAren Dermarderosian
Aren Dermarderosian
DTDerek Tai
Derek Tai
MAMojtaba Akhtari
Mojtaba Akhtari
Localized amyloidosis is a rare benign disease characterized by extracellular deposition of misfolded proteins in a specific organ without systemic involvement, which might lead to organ dysfunction. Patients with localized amyloidosis do not develop systemic diseases such as cardiac, renal, hepatic, or nerve involvement. Typically, the localized disease is managed by surgical resection, while the systemic disease is treated with a combination chemotherapy and immunotherapy. However, some patients can have challenging clinical presentations, delaying diagnosis and organ dysfunction, and they might require systemic therapeutic intervention. There is a significant paucity of knowledge and data regarding clinical manifestations and the course of localized amyloidosis in various organs, and management can also be challenging. It is crucial to appropriately balance effective therapy with patient safety as treatment can lead to toxicity. Here, we discuss a series of patients who were presented with localized amyloidosis and one of whom needed systemic therapy.

Verified
Journal Article
Open access
PDF file
KKKyung-il John Kim
Kyung-il John Kim
HZHannah Zhong
Hannah Zhong
DTDerek Tai
Derek Tai
PSPranati Shah
Pranati Shah
DPDaniel Park
Daniel Park
DCDani Ran Castillo
Dani Ran Castillo
Gastric cancer (GC), often diagnosed at advanced or metastatic stages, remains a significant clinical challenge requiring novel biomarkers for early detection, risk stratification, and effective, personalized treatment optimization. Emerging evidence underscores a strong association between gut microbiome dysbiosis and GC initiation, progression, and therapeutic outcomes. This review explores the potential of the advanced/metastatic gastric microbiome as a source of diagnostic and targetable biomarkers and its role in modulating responses to immunotherapy. Although Helicobacter pylori (H. pylori) is the most significant risk factor for GC, several other gastrointestinal taxa—including Fusobacterium nucleatum (F. nucleatum)—have been implicated in advanced GC (AGC). At its inception, microbial dysbiosis contributes to chronic inflammation and immune evasion, thereby influencing tumor behavior and treatment efficacy. Integrating microbiome-based biomarkers into risk stratification, GC staging, and targetable treatment frameworks may enhance early detection, inform immunotherapy strategies, and improve patient-specific treatment responses. Bifidobacterium and Lactobacillus rhamnosus GG have the potential to change the immunotherapy framework with their direct influence on dendritic cell (DC) and cytotoxic T cell (CTL) activity. However, clinical translation is impeded by methodological heterogeneity, causality limitations, and a lack of clinical trials. Nonetheless, the integration of microbiome profiling and the development of therapeutic microbiome modulation strategies, such as personalized probiotics regimens and fecal microbiota transplantation, hold substantial potential for improving clinical outcomes and reducing treatment-related toxicity in GC management.

29 April 2025 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
DTDerek Tai
Derek Tai
DPDaniel Park
Daniel Park
PSPriscilla Soria
Priscilla Soria
PSPranati Shah
Pranati Shah
KWKendall Wick
Kendall Wick
MAMojtaba Akhtari
Mojtaba Akhtari
Inotuzumab (InO) is an anti-CD22 immunoconjugate for patients with relapsed or refractory CD22 positive B-cell acute lymphoblastic leukemia (B-ALL). Liver toxicity is a recognized side effect of InO, including sinusoidal obstruction syndrome (SOS), but is not fully understood. This study describes a new aspect of InO-induced hepatotoxicity by outlining six patients who developed abnormal liver function tests (LFTs) and thrombocytopenia, with liver biopsies showing sinusoidal congestion without evidence of SOS. Liver biopsies were obtained from all six patients and LFTs were monitored before initiating InO treatment, during treatment, and after discontinuing treatment. All six patients experienced abnormal LFTs at a median of 15 days after the last dose of InO and improvement in LFTs at a median of 17 days after discontinuing InO. Initial baseline AST, ALT, ALP, and total bilirubin values prior to InO therapy ranged from 10–45 U/L, 10–45 U/L, 60–207 U/L, and 0.2–0.9 mg/dL respectively and increased up to 2 to 4 times the upper limit of normal after completing varying cycles of InO with hepatotoxicity grades ranging from 1–2. LFTs returned to 1 to 1.5 times the upper limit of normal after discontinuing InO. The patients’ liver biopsies all demonstrated different levels of hepatic sinusoidal congestion (HSC) without evidence of SOS. This study provides new evidence describing HSC, where we hypothesize that InO induced hepatotoxicity are due to calicheamicin. We propose a new clinical entity called “calicheamicin syndrome” with its quadriad components: History of using InO or GO, elevated LFTs, thrombocytopenia, and abnormal liver imaging.

8 June 2026 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
DTDerek Tai
Derek Tai
KLKareem Latif
Kareem Latif
PSPranati Shah
Pranati Shah
GSGajaan Sittambalam
Gajaan Sittambalam
RDRahel Demisse
Rahel Demisse
LLLouisa Liu
Louisa Liu
Ultra-processed foods (UPFs), which NOVA classification defines as industrial formulations composed largely of refined ingredients and additives, now account for a majority of caloric intake in many high-income countries. Epidemiologic evidence suggests high UPF consumption may contribute to gastrointestinal (GI) malignancies independent of traditional nutrient-based dietary metrics. This review examines associations between UPF intake and colorectal, gastric, esophageal, and pancreatic cancers, integrating mechanisms supporting biological plausibility. The association between UPF consumption and colorectal cancer is the most consistent, with 10-30% increased risk among individuals with the highest intake. Evidence also suggests associations with non-cardia gastric cancer and esophageal adenocarcinoma, although data remain limited. Findings for pancreatic cancer are inconclusive. Mechanistically, ultra-processing may promote carcinogenesis through multiple pathways. Disruption of the food matrix and rapid glycemic absorption may activate insulin and insulin-like growth factor signaling. Low fiber content and additive exposure may alter the gut microbiome, reduce short-chain fatty acid production, impair intestinal barrier integrity, and promote chronic inflammation. Nitrates, nitrites, and emulsifiers in UPFs demonstrate pro-inflammatory and carcinogenic effects in experimental models. Although observational design limits causal inference, the consistency of epidemiologic associations, dose-response relationships, and supporting mechanistic data suggest UPF reduction may represent a potential GI cancer prevention strategy.

31 July 2026 in Cancer Medicine
Verified
Journal Article
Open access
DCDani Ran Castillo
Dani Ran Castillo
PSPranati Shah
Pranati Shah
DTDerek Tai
Derek Tai
MGMengni Guo
Mengni Guo
MHMax Hazeltine
Max Hazeltine
SWShengyang Wu
Shengyang Wu
Introduction: Early‐onset gastric cancer (EOGC), defined as diagnosis before age 45, represents a distinct and increasingly recognized subset of gastric cancer. Emerging evidence suggests that clinical behavior, treatment patterns, and outcomes differ from average‐onset disease, yet these differences remain incompletely characterized. We evaluated demographic, geographic, pathologic, treatment, and survival patterns in patients with EOGC. Methods: This retrospective cohort study included patients with stage II–III gastric cancer diagnosed between 2006 and 2022 who underwent curative‐intent gastrectomy in the National Cancer Database (NCDB). EOGC was defined as age ≤ 45 years at diagnosis. Demographic, pathologic, and treatment variables were analyzed. Overall survival (OS) was estimated using Kaplan–Meier methods and Cox proportional hazards models. A landmark analysis excluding patients with < 6 months of follow‐up addressed survivorship bias. Results: Across nearly two decades, EOGC accounted for 7.3% of the cohort and demonstrated demographic and geographic concentration, particularly among Hispanic, Black, and Asian patients. EOGC was associated with aggressive clinicopathologic features, including diffuse or signet‐ring histology, poor differentiation, and advanced nodal disease. Although patients with EOGC more frequently received perioperative or neoadjuvant chemotherapy compared with older cohorts, pathologic complete response rates remained low, underscoring limited benefit from treatment intensification alone. Conclusions: Despite receipt of more intensive multimodality therapy, EOGC did not demonstrate superior survival outcomes. These findings highlight EOGC as a clinically distinct, high‐risk disease subtype and support the need for biomarker‐driven therapeutic strategies and earlier detection efforts in high‐risk populations.